We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Novavax Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, has updated its leadership team and appointed Gregory F. Covino as executive vice president and chief financial officer (CFO).